{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PRPH","limit":50},"count":50,"signals":[{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"set forth in Section 5.2. Section 1.26. Investor Indemnitees shall have the meaning set forth in Section 5.1(a). Section 1.27. Losses shall have the meaning set forth in Section 5.1(b). Section 1.28. Material Adverse Effect shall mean any condition, circumstance, or situation that may result in, or reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of the Agreem","filed_date":"2026-01-23","accession":"0001493152-26-003456","full_text":"https://origin.rootz.global/static/filing/0001493152-26-003456.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"Genomics is accredited by the Better Business Bureau (BBB) with a current B rating in the DNA Testing / Genetic Testing category. A number of customer inquiries and complaints relating to order fulfillment, billing, and access to results have been reported. Due to a change in sequencing lab, the companies fell behind in sequencing. A new lab has been engaged and the delayed results are in the proces","filed_date":"2025-11-19","accession":"0000868278-25-000017","full_text":"https://origin.rootz.global/static/filing/0000868278-25-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"egatively impact our reputation, regardless of the ultimate outcome or our current assessment of materiality. There is no assurance that this matter or other litigation that may arise will not have a material adverse effect on our business, results of operations, or financial condition in the future. In October 2024, a putative class action lawsuit, *Portillo v. Nebula Genomics, Inc.*, was filed in the U.S. District Cou","filed_date":"2025-10-21","accession":"0001493152-25-018819","full_text":"https://origin.rootz.global/static/filing/0001493152-25-018819.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"| 12/31/2030 | | | |  Robert Morse | |  | - | (5) | |  | - | (5) | |  | - | | |  | - | | | |  (1) |  Award of 500,000 options was granted on April 4, 2024 was scheduled to vest in 5 equal annual installments beginning on April 4, 2024, subject to Mr. Karkus continued service through each vesting date. | | |  |  | | |  (2) |  Award of 400,000 options was granted on March 17, 2024 was scheduled to vest","filed_date":"2025-08-15","accession":"0001641172-25-024375","full_text":"https://origin.rootz.global/static/filing/0001641172-25-024375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ibed to such term in Section 4.01(c). Liens shall mean a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction or adverse claim of a third party. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.01(b). Money Laundering Laws has the meaning ascribed to such term in Section 3.01(hh). OID means 20%. Original Principal Amount means, with","filed_date":"2025-07-28","accession":"0001641172-25-021109","full_text":"https://origin.rootz.global/static/filing/0001641172-25-021109.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"w School in May 1997, an M.B.A. in General Management with a concentration in financial management from SDA Bocconi School of Management, Universita Luigi Bocconi in Milan, Italy in December 1998, an LLM in Corporate Taxation from New York Law School in May 2007, and an LLM in Commercial Real Estate Financing from New York Law School in May 2009. She is a practicing attorney and a member of the Bar o","filed_date":"2025-06-23","accession":"0001641172-25-016010","full_text":"https://origin.rootz.global/static/filing/0001641172-25-016010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"t to approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the four nominees for director who receive the highest number of votes FOR their election will be elected as directors. This is called a plurality vote. The ratification of our independent registered public accounting firm (Proposal 2) will require the affirmative vote of a majority of the votes cast on such proposa","filed_date":"2025-06-23","accession":"0001641172-25-016010","full_text":"https://origin.rootz.global/static/filing/0001641172-25-016010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"a lump sum within five business days following the effective date of the termination; and (y) the remaining one-half of the cash severance payment will be paid in 12 equal, consecutive, monthly installments commencing on the first business day of the month following the effective date of the termination; and | | |  |  |  | | |  |  |  All of his outstanding and unvested stock options and/or restricte","filed_date":"2025-04-30","accession":"0001641172-25-007899","full_text":"https://origin.rootz.global/static/filing/0001641172-25-007899.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"ementation of corporate strategies. Another advantage is the clarity of leadership provided by one person representing the Company to employees, stockholders and other stakeholders. The Board has not named a lead independent director. **Risk Oversight** Our Board is actively involved in oversight of risks that could affect us. This oversight is conducted primarily by our full Board, which has responsibility for general oversight","filed_date":"2025-04-30","accession":"0001641172-25-007899","full_text":"https://origin.rootz.global/static/filing/0001641172-25-007899.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"and AI technology present various operational, compliance and reputational risks and if any such risks were to materialize, our business and results of operations may be adversely affected.  We have integrated AI into our production processes and may continue to integrate machine learning and AI. We may continue to integrate machine learning and AI technology into other aspects of our business. Given that machine","filed_date":"2025-04-01","accession":"0000868278-25-000003","full_text":"https://origin.rootz.global/static/filing/0000868278-25-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"ness. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on our business. In addition, compliance with future legislation could impose additional requirements on us, which may be costly. Health Insurance Portability and Accountability Act The Health Insura","filed_date":"2025-04-01","accession":"0000868278-25-000003","full_text":"https://origin.rootz.global/static/filing/0000868278-25-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"r property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. | 8 | | **Section 4.2","filed_date":"2025-01-30","accession":"0001493152-25-004210","full_text":"https://origin.rootz.global/static/filing/0001493152-25-004210.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"a $7,800 vehicle allowance, and a $20,800 matching contribution in the Companys 401(k) defined contribution plan. He also received stock options with a value of $150,000 that vest in four equal installments starting on the grant date. The compensation paid to Mr. Karkus was approved by the Companys compensation committee and audit committee. | | 17 | | | **EXECUTIVE OFFICERS** The following table an","filed_date":"2024-05-15","accession":"0001493152-24-019839","full_text":"https://origin.rootz.global/static/filing/0001493152-24-019839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"t to approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the four nominees for director who receive the highest number of votes FOR their election will be elected as directors. This is called a plurality vote. The ratification of our independent registered public accounting firm (Proposal 2) will require the affirmative vote of a majority of the votes cast on such proposa","filed_date":"2024-05-15","accession":"0001493152-24-019839","full_text":"https://origin.rootz.global/static/filing/0001493152-24-019839.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"and AI technology present various operational, compliance and reputational risks and if any such risks were to materialize, our business and results of operations may be adversely affected.  We have integrated AI into our production processes and may continue to integrate machine learning and AI. We may continue to integrate machine learning and AI technology into other aspects of our business. Given that machine","filed_date":"2024-03-29","accession":"0000868278-24-000004","full_text":"https://origin.rootz.global/static/filing/0000868278-24-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":45,"context":"ness. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on our business. In addition, compliance with future legislation could impose additional requirements on us, which may be costly. Health Insurance Portability and Accountability Act The Health Insura","filed_date":"2024-03-29","accession":"0000868278-24-000004","full_text":"https://origin.rootz.global/static/filing/0000868278-24-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"a bonus of $850,000 for his significant contributions related to the revenue growth of ProPhase Diagnostics, Inc. He also received stock options with a value of $468,000 that vest in four equal installments starting on the grant date. For 2022, Mr. Jason Karkus received an annual base salary of $220,000, a bonus of $300,000 for his significant contributions related to the growth of ProPhase Diagnost","filed_date":"2023-04-27","accession":"0001493152-23-013776","full_text":"https://origin.rootz.global/static/filing/0001493152-23-013776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"t to approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the four nominees for director who receive the highest number of votes FOR their election will be elected as directors. This is called a plurality vote. The ratification of our independent registered public accounting firm (Proposal 2), the proposal to approve the Amended and Restated 2022 Equity Compensation Plan (","filed_date":"2023-04-27","accession":"0001493152-23-013776","full_text":"https://origin.rootz.global/static/filing/0001493152-23-013776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"ization of Equivir as a dietary supplement, leveraging our distribution in over 40,000 food, drug and mass (FDM) retail stores and online direct to consumers.  In March 2023, we commenced patient enrollment in a randomized, placebo-controlled clinical trial of Equivir to evaluate its effect on upper respiratory tract infections. Vedic Lifesciences, a leading clinical research organization, is contrac","filed_date":"2023-03-29","accession":"0000868278-23-000004","full_text":"https://origin.rootz.global/static/filing/0000868278-23-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"g claims, or failure to accurately bill for testing services, could have an adverse effect on our revenue. The loss of sales to any one or more of our large diagnostic services customers could have a material adverse effect on our business operations and financial condition. If we fail to comply with the complex federal, state, local and foreign laws and regulations, we could suffer severe consequences that could materi","filed_date":"2023-03-29","accession":"0000868278-23-000004","full_text":"https://origin.rootz.global/static/filing/0000868278-23-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"| | |  |  (4) |  To consider and act upon a proposal to approve the 2022 Directors Equity Compensation Plan; | | |  |  |  | | |  |  (5) |  To hold an advisory vote to approve the compensation of our named executive officers; and | | |  |  |  | | |  |  (6) |  To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. | | These items of business are more","filed_date":"2022-04-13","accession":"0001493152-22-009841","full_text":"https://origin.rootz.global/static/filing/0001493152-22-009841.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"rvices customers accounted for 23.5%, 17.9%, and 11.9% of our Fiscal 2021 revenues from continuing operations. The loss of sales to any one or more of these diagnostic services customers could have a material adverse effect on our business operations and financial condition, unless we are able to increase revenue from other sources. Collections of diagnostic services revenues are driven by payers, which are government a","filed_date":"2022-03-31","accession":"0001493152-22-008541","full_text":"https://origin.rootz.global/static/filing/0001493152-22-008541.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on or affect the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders equity or results of operations of the Company or prevent or materiall","filed_date":"2021-12-29","accession":"0001493152-21-032692","full_text":"https://origin.rootz.global/static/filing/0001493152-21-032692.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Companys failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition. | 9 | | | | | **ProPhase Labs, Inc. and Subsidiaries** **Notes to Condensed Consolidated Financial Statements** **(unaudite","filed_date":"2021-11-12","accession":"0001493152-21-028235","full_text":"https://origin.rootz.global/static/filing/0001493152-21-028235.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"18 Stock Incentive Plan on February 23, 2018 to purchase 2,300,000 shares of Common Stock of the Company at an initial exercise price of $3.00 per share, which is exercisable in 35 equal monthly installments of 63,888 shares on the first day of each month beginning on March 1, 2018 (the Initial Vesting Date), and one monthly installment of 63,920 shares on the first day of the 36th month following th","filed_date":"2021-04-16","accession":"0001493152-21-008994","full_text":"https://origin.rootz.global/static/filing/0001493152-21-008994.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"t to approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the four nominees for director who receive the highest number of votes FOR their election will be elected as directors. This is called a plurality vote. | | Approval of the ratification of our independent registered public accounting firm (Proposal 2), the proposal to approve the Amended and Restated 2010 Equity Com","filed_date":"2021-04-16","accession":"0001493152-21-008994","full_text":"https://origin.rootz.global/static/filing/0001493152-21-008994.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"or 47.1% and 17.2%, respectively, of our Fiscal 2020 revenues from continuing operations. The loss of sales to any one or more of these large third-party contract manufacturing customers could have a material adverse effect on our business operations and financial condition, unless we are able to increase revenue from other sources. | | 4 | | | | | | | | **TK Supplements Product Line** Our TK Supplements product line is","filed_date":"2021-03-31","accession":"0001493152-21-007538","full_text":"https://origin.rootz.global/static/filing/0001493152-21-007538.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ID-19 will negatively impact our financial results or liquidity. The COVID-19 pandemic has also had a negative impact on the global capital markets and economies worldwide and could ultimately have a material adverse impact on our ability to raise capital needed to operate our business. In addition, a prolonged recession or market correction resulting from the spread of the coronavirus could affect the value of our comm","filed_date":"2020-11-19","accession":"0001493152-20-022041","full_text":"https://origin.rootz.global/static/filing/0001493152-20-022041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the four nominees for director who receive the highest number of votes cast FOR their election will be elected as directors. This is called a plurality vote. | | Approval of the ratification of our independent registered public accounting firm (Proposal 2) will require the affirmative vote of a majority of the votes cast","filed_date":"2020-04-16","accession":"0001493152-20-006542","full_text":"https://origin.rootz.global/static/filing/0001493152-20-006542.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"%, 30.5% and 11.1%, respectively, of our Fiscal 2019 revenues from continuing operations. The loss of sales to any one or more of these large third-party contract manufacturing customers could have a material adverse effect on our business operations and financial condition, unless we are able to increase revenue from other sources. | | 4 | | | | | | ** ** **TK Supplements Product Line** Our TK Supplements product line","filed_date":"2020-03-26","accession":"0001493152-20-004807","full_text":"https://origin.rootz.global/static/filing/0001493152-20-004807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"our independent registered public accounting firm for the fiscal year ending December 31, 2019 (Proposal 2); | | |  |  |  | | |  |  (3) |  To hold an advisory vote to approve the compensation of our named executive officers (the Say-on-Pay Vote) (Proposal 3); | | |  |  |  | | |  |  (4) |  To hold an advisory vote on the frequency of future Say-on-Pay Votes (Proposal 4); and | | |  |  |  | | |  |  (5) |  To transact suc","filed_date":"2019-04-19","accession":"0001493152-19-005646","full_text":"https://origin.rootz.global/static/filing/0001493152-19-005646.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":", 31.1%, and 10.9%, respectively, of our Fiscal 2018 revenues from continuing operations. The loss of sales to any one or more of these large third-party contract manufacturing customers could have a material adverse effect on our business operations and financial condition, unless we are able to increase revenue from other sources. | -4- | | | | | **TK Supplements Product Line** ** ** Our TK Supplements product line is","filed_date":"2019-03-26","accession":"0001493152-19-003946","full_text":"https://origin.rootz.global/static/filing/0001493152-19-003946.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"t to approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the four nominees for director who receive the highest number of votes FOR their election will be elected as directors. This is called a plurality vote. | | Approval of the ratification of our independent registered public accounting firm (Proposal 2), the proposal to approve the Amended and Restated 2010 Equity Com","filed_date":"2018-04-19","accession":"0001493152-18-005427","full_text":"https://origin.rootz.global/static/filing/0001493152-18-005427.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":", 16.1%, and 11.1%, respectively, of our Fiscal 2017 revenues from continuing operations. The loss of sales to any one or more of these large third-party contract manufacturing customers could have a material adverse effect on our business operations and financial condition, unless we are able to increase revenue from other sources. | 4 | | **TK Supplements Product Line** ** ** Our TK Supplements product line is dedicat","filed_date":"2018-03-28","accession":"0001493152-18-004041","full_text":"https://origin.rootz.global/static/filing/0001493152-18-004041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ment agreement) (Karkus Severance). One-half of the Karkus Severance payment would be paid as a lump sum payment in cash and the remaining one-half would be paid in 12 equal consecutive, monthly installments commencing on the first business day of the month following the effective date of the termination. In addition, Mr. Karkus, and his eligible dependents, would be entitled to Company-paid COBRA co","filed_date":"2018-03-23","accession":"0001493152-18-003776","full_text":"https://origin.rootz.global/static/filing/0001493152-18-003776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"k as of February 26, 2018 by (a) each person known to the Company to own more than 5% of the outstanding shares of our Common Stock, (b) each director and nominee for director of the Company, (c) the named executive officers and (d) all directors and executive officers as a group. Unless otherwise indicated, the address of each person or entity listed below is the Companys principal executive office. |  Name of Benefici","filed_date":"2018-03-23","accession":"0001493152-18-003776","full_text":"https://origin.rootz.global/static/filing/0001493152-18-003776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ur Company and brand image, and our standard of proven consumer benefit and efficacy. Management is not aware of any other trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity, or (ii) net sales or income from continuing operations. Any challenge to our patent or trademark rights could have a material adverse effect on our fut","filed_date":"2017-05-15","accession":"0001493152-17-005292","full_text":"https://origin.rootz.global/static/filing/0001493152-17-005292.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":39,"context":"t to approve each of the proposals? | | |  |  | | |  A: |  In the election of directors (Proposal 1), the five nominees for director who receive the highest number of votes FOR their election will be elected as directors. This is called a plurality vote. | | Approval of the ratification of our independent registered public accounting firm (Proposal 2) will require the affirmative vote of a majority of the votes cast","filed_date":"2017-04-20","accession":"0001493152-17-004215","full_text":"https://origin.rootz.global/static/filing/0001493152-17-004215.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"and conditions required by the Asset Purchase Agreement and each of the other Transaction Documents to be performed or complied with by it on or before the closing date; | | |  |  |  | | |  |  |  no material adverse effect, event, development or change in the results of operations of the Cold-EEZE Business or the Acquired Assets will have occurred; and | | |  |  |  | | |  |  |  we will have delivered to Mylan all deliv","filed_date":"2017-03-03","accession":"0001493152-17-002086","full_text":"https://origin.rootz.global/static/filing/0001493152-17-002086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"pproximately 18.9%, 16.9% and 11.3%, respectively, of our Fiscal 2014 revenues. The loss of sales to any one or more of these large retail or third party contract manufacturing customers could have a material adverse effect on our business operations and financial condition, unless we are able to increase revenue from other sources. | 8 | | | | | | | In addition, we have entered into multiple broker, distributor and rep","filed_date":"2017-02-24","accession":"0001493152-17-001890","full_text":"https://origin.rootz.global/static/filing/0001493152-17-001890.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":53,"context":"ment of EisnerAmper LLP as independent auditors for the year ending December 31, 2016; | | |  |  |  | | |  |  (4) |  To approve the advisory (non-binding) resolution regarding the compensation of our named executive officers; and | | |  |  |  | | |  |  (5) |  To transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. | | Only stockholders of record at th","filed_date":"2016-04-18","accession":"0001493152-16-009008","full_text":"https://origin.rootz.global/static/filing/0001493152-16-009008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"eens, Wal-Mart and CVS accounted for approximately 20.4%, 14.3% and 11.6%, respectively, of our Fiscal 2013 revenues. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition. | | - 5 - | | | In addition, we have entered into multiple broker, distributor and representative agreements with third parties which provide for c","filed_date":"2016-03-29","accession":"0001493152-16-008343","full_text":"https://origin.rootz.global/static/filing/0001493152-16-008343.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rship or lease of real or personal property for use in the operation of the Companys business or (b) the nature of the business conducted by the Company except where failure to do so would not have a material adverse effect on the Company. The Company has all requisite power, right and authority to own, operate and lease its properties and assets, to carry on its business as now conducted, to execute, deliver and perfor","filed_date":"2015-12-16","accession":"0001493152-15-006274","full_text":"https://origin.rootz.global/static/filing/0001493152-15-006274.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"vider of Identity Access Management and Multi-Factor Authentication solutions offering advanced information technology through its solutions to the government and commercial markets. Mr. McCubbin was promoted to Executive Vice President and Chief Financial Officer of WidePoint in May 2008. Prior to that time, from August 1998 till May 2008, Mr. McCubbin served as WidePoints Vice President and Chief Financial Officer. Prior to that t","filed_date":"2015-05-11","accession":"0001144204-15-028958","full_text":"https://origin.rootz.global/static/filing/0001144204-15-028958.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"eens, Wal-Mart and CVS accounted for approximately 19.3%, 13.8% and 13.4%, respectively, of our Fiscal 2012 revenues. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition. In addition, we have entered into multiple broker, distributor and representative agreements with third parties which provide for commission compen","filed_date":"2015-03-27","accession":"0001144204-15-018860","full_text":"https://origin.rootz.global/static/filing/0001144204-15-018860.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"vider of Identity Access Management and Multi-Factor Authentication solutions offering advanced information technology through its solutions to the government and commercial markets. Mr. McCubbin was promoted to Executive Vice President and Chief Financial Officer of WidePoint in May 2008. Prior to that time, from August 1998 till May 2008, Mr. McCubbin served as WidePoints Vice President and Chief Financial Officer. Prior to that t","filed_date":"2014-04-09","accession":"0001144204-14-021526","full_text":"https://origin.rootz.global/static/filing/0001144204-14-021526.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ite-Aid Corp (Rite Aid) accounted for approximately 17%, 14%, 13% and 12%, respectively, of our Fiscal 2011 revenues. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition. In addition, we have entered into multiple broker, distributor and representative agreements with third parties which provide for commission compen","filed_date":"2014-03-27","accession":"0001144204-14-018406","full_text":"https://origin.rootz.global/static/filing/0001144204-14-018406.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":38,"context":"r of shares issuable thereunder by one hundred seventy five thousand (175,000) shares; |  | |  |  (5) |  To consider and approve an advisory (non-binding) resolution regarding the compensation of our named executive officers; |  | |  |  (6) |  To consider and act upon an advisory (non-binding) vote on the frequency at which the Company should include an advisory vote regarding the compensation of our named executive off","filed_date":"2013-04-03","accession":"0001144204-13-019806","full_text":"https://origin.rootz.global/static/filing/0001144204-13-019806.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"reens, Wal-Mart and Rite Aid accounted for approximately 23%, 14% and 10%, respectively, of our Fiscal 2010 revenues. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition. | - 7 - | | | | | In addition, we have entered into multiple broker, distributor and representative agreements with third parties which provide for","filed_date":"2013-03-28","accession":"0001144204-13-018178","full_text":"https://origin.rootz.global/static/filing/0001144204-13-018178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PRPH","company":"ProPhase Labs, Inc.","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"0 revenues. CVS, Walgreens and Wal-Mart accounted for approximately 15%, 15% and 13% of our revenues for Fiscal 2009. The loss of sales to any one or more of these large retail customers could have a material adverse effect on our business operations and financial condition. In addition, we have several national Broker, Distributor and Representative Agreements which provide for commission compensation based on sales pe","filed_date":"2012-03-07","accession":"0001144204-12-013420","full_text":"https://origin.rootz.global/static/filing/0001144204-12-013420.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"1b1ef05875c92a534ef29018b6fec796423496469be6ae2853e55597cc3628f5","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"0db63405a8f9adaae78a093abd1df10d14c93f3ac4a2133c0344b3235d129979","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":110,"hourly_limit":500,"remaining":390,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}